Search

Novel basis for chemoresistance in AML: DNMT3A R882 mutations promote chemoresistance and residual disease through impaired DNA damage sensing

Although most acute myeloid leukemia (AML) patients initially respond to chemotherapy, the majority subsequently relapses and succumbs to refractory disease. Residual leukemic cells that survived chemotherapy may persist over time and later cause the disease to come back.

Read more

Abstract & travel grant submission

Abstract submission is closed

Abstract procedurePlease note that the submission of an abstract constitutes a formal commitment by the presenting author to present the abstract (if accepted) orally or as a poster in the session at the time assigned by the…

Read more

EHA-SWG Scientific Meeting on Immunotherapy for Hematological Disorders

EHA and the Scientific Working Group on Immunotherapy for Hematological Disorders are happy to announce the redesigned fully virtual meeting program to meet the needs of hematologists and immunologists in these challenging times.

Read more

ASCAT 2023

EHA joins forces with the British Society of Haematology (BSH) & Annual Academy of Sickle Cell and Thalassaemia Conference (ASCAT) in organizing the 18th Annual Sickle Cell & Thalassaemia Conference.

Read more

ASCAT2024

EHA joins forces with the British Society of Haematology (BSH) & Annual Academy of Sickle Cell and Thalassaemia Conference (ASCAT) in organizing the 19th Annual Sickle Cell & Thalassaemia Conference.

Read more